Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
Public ClinicalTrials.gov record NCT03070782. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-Controlled, Dose-Ranging Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) Administered Subcutaneously to Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease (CVD)
Study identification
- NCT ID
- NCT03070782
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Akcea Therapeutics
- Industry
- Enrollment
- 286 participants
Conditions and interventions
Conditions
Interventions
- ISIS 681257 Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 6, 2017
- Primary completion
- Jul 25, 2018
- Completion
- Nov 12, 2018
- Last update posted
- Oct 29, 2020
2017 – 2018
United States locations
- U.S. sites
- 22
- U.S. states
- 15
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Site | Cottonwood | Arizona | 86326 | — |
| Clinical Site | Huntington Beach | California | 92648 | — |
| Clinical Site | La Jolla | California | 92103 | — |
| Clinical Site | Los Angeles | California | 90048 | — |
| Clinical Site | Stanford | California | 94305 | — |
| Clinical Site | Colorado Springs | Colorado | 80909 | — |
| Clinical Site | Boca Raton | Florida | 33434 | — |
| Clinical Site | Jacksonville | Florida | 32216 | — |
| Clinical Site | Kansas City | Kansas | 66160 | — |
| Clinical Site | Baltimore | Maryland | 21201 | — |
| Clinical Site | Boston | Massachusetts | 02114 | — |
| Clinical Site | Cooperstown | New York | 13326 | — |
| Clinical Site | New York | New York | 10016 | — |
| Clinical Site | New York | New York | 10029 | — |
| Clinical Site | Cleveland | Ohio | 44195 | — |
| Clinical Site | Portland | Oregon | 97239 | — |
| Clinical Site | Lancaster | Pennsylvania | 17602 | — |
| Clinical Site | Philadelphia | Pennsylvania | 19104 | — |
| Clinical Site | Providence | Rhode Island | 02906 | — |
| Clinical Site | Houston | Texas | 77030 | — |
| Clinical Site | Falls Church | Virginia | 22042 | — |
| Clinical Site | Milwaukee | Wisconsin | 53215 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03070782, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2020 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03070782 live on ClinicalTrials.gov.